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Abstract
Background:  Dihydroartemisinin (DHA), a powerful anti-malarial drug, has been used as
monotherapy and artemisinin-based combination therapy (ACT) for more than decades. So far,
however, the tissue distribution and metabolic profile of DHA data are not available from animal
and humans.
Methods: Pharmacokinetics, tissue distribution, mass balance, and elimination of [14C] DHA have
been studieded in rats following a single intravenous administration. Protein binding was performed
with rat and human plasma. Drug concentrations were obtained up to 192 hr from measurements
of total radioactivity and drug concentration to determine the contribution by the parent and
metabolites to the total dose of drug injected from whole blood, plasma, urine and faecal samples.
Results: Drug was widely distributed after 1 hr and rapidly declined at 24 hr in all tissues except
spleen until 96 hrs. Only 0.81% of the total radioactivity was detected in rat brain tissue. DHA
revealed a high binding capacity with both rat and human plasma proteins (76–82%). The
concentration of total radioactivity in the plasma fraction was less than 25% of that in blood total.
Metabolism of DHA was observed with high excretion via bile into intestines and approximately
89–95% dose of all conjugations were accounted for in blood, urine and faeces. However, the
majority of elimination of [14C] DHA was through urinary excretion (52% dose). The mean
terminal half-lives of plasma and blood radioactivity (75.57–122.13 h) were significantly prolonged
compared with that of unchanged DHA (1.03 h).
Conclusion: In rat brain, the total concentration of [14C] was 2-fold higher than that in plasma,
indicating the radioactivity could easily penetrate the brain-blood barrier. Total radioactivity
distributed in RBC was about three- to four-fold higher than that in plasma, suggesting that the
powerful anti-malarial potency of DHA in the treatment of blood stage malaria may relate to the
high RBC binding. Biliary excretion and multiple concentration peaks of DHA have been
demonstrated with high urinary excretion due to a most likely drug re-absorption in the intestines
(enterohepatic circulation). The long lasting metabolites of DHA (> 192 hr) in the rats may be also
related to the enterohepatic circulation.
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Background
Dihydroartemisinin (DHA) is the active metabolite of the
more widely used artesunate and artemether. DHA is
manufactured as an oral anti-malarial drug used in south-
ern Asia and Africa. Recently, Walter Reed Army Institute
of research (WRAIR) (explicit abbreviation) has chosen
artesunate (AS) injection as the blood stage compound for
severe and complicated malaria and it has been demon-
strated that AS is a pro-drug of DHA [1], which has same
efficacy to AS and is three to five times more active than
the other artemisinin derivatives [2-5]. Artesunate is a
more potent anti-malarial drug than arteether and arte-
mether, which may be explained by the conversion to
DHA with the DHA/AS ratios of 0.31–2.74 in animal spe-
cies [6,7], and 2.81–9.71 in malaria humans [8,9]. A study
demonstrated that only DHA was rapidly effective against
all stages of the parasite life cycle and completely inhib-
ited the parasite growth within the shortest exposure time
when compared to all other artemisinin drugs [10]. It is
also felt by many clinicians that AS administered intrave-
nously is the most effective for treatment of severe malaria
due to the high DHA levels [11].
Cotecxin® (DHA tablet) has been used in China and Thai-
land since 1991 [12]. Given alone, however, this artemisi-
nin derivative must be given daily for seven days for
optimum cure rates. Five-day regimens give lower cure
rates and three-day regimens of artemisinin monotherapy
are associated with very high failure rates (40–80%) in
malaria patients [13]. It is widely accepted that artemisi-
nin-based combination therapy (ACT) provides the best
available treatment for uncomplicated multidrug-resist-
ant falciparum malaria [14,15]. ACT gives reliably rapid
therapeutic responses, provides high cure rates with three-
day treatment regimens, is well tolerated, reduces gameto-
cyte carriage and provides mutual protection for the part-
ner drugs against the emergence of resistance [16]. DHA-
piperaquine (Artekin®) has a cost advantage over other
combinations (US$ 1 for an adult treatment) making it a
potential best candidate for deployment in Vietnam,
Southeast Asia and Africa [17].
Although the use of DHA has spread rapidly and pharma-
cokinetic research in animals and humans has been done,
basic questions regarding tissue distribution, protein
binding, and metabolic profile of DHA, especially follow-
ing intravenous treatment, have not been answered. The
tissue distribution investigation of radiolabeled AS had
been conducted by Li et al. [18]. Radioactivity derived
from [14C]-AS was eliminated from plasma in three
phases with half-lives of 0.12, 13.2, and 76.2 hours.
Unchanged AS was eliminated from plasma in two appar-
ent phases with half-lives of 0.14 and 0.43 hours, suggest-
ing that the total radioactivity of AS lasted much longer
than unchanged AS in rats. Through 192 hours after injec-
tion, approximately 56%, 38%, and 1.6% of the dose was
eliminated via urine, faeces, and cage rinses, respectively.
Unchanged AS was eliminated within one hour, indicat-
ing long-lasting radioactivity may be the result of AS
metabolites including DHA [18].
However, there is no information on the disposition and
excretion of DHA after intravenous injection of its parent
drug, AS. Also, previous papers did not discriminate the
metabolic profiles of AS and DHA. The present study was
undertaken to ascertain the pharmacokinetics, tissue dis-
tribution, mass balance, and elimination of radiolabeled
DHA in rats and protein binding in both of rat and human
plasma. In accordance with FDA guidance [19], any par-
ent compound and its major metabolite(s) that achieve,
or are expected to achieve, systemic exposure in human
should be evaluated in pharmacology studies prior to
human clinical trials [19]. In the present study, DHA was
administered intravenously in male rats for pharmacoki-




The test unlabeled compound used in this study is dihy-
droartemisinin (10'dihydro-artemisinin, DHA), which
was prepared as a 25% cremophore/0.9% saline solution.
Unlabeled DHA was synthesized and manufactured by
Knoll AG (Switzerland) and repackaged by BASF Pharma-
ceuticals (Ludwigshafen, Germany). It was supplied
through the Division of Experimental Therapeutics at
Walter Reed Army Institute of Research (WRAIR, Silver
Spring, Maryland, USA). The lot of [16-14C] DHA (Lot No.
10839-113) used in this study and was synthesized by
Research Triangle Institute (Research Triangle Park, North
Carolina, USA). The stated specific activity and radio-
chemical purity was 21.83 mCi/mmol (77.3 μCi/mg) and
98.0%, respectively. Unlabeled DHA and radiolabeled
compounds were stored at approximately -20°C.
Animals
Male Sprague-Dawley rats obtained from Charles River
Laboratories (Wilmington Massachusetts, USA) were used
in this study. On arrival, the animals were acclimated for
seven days (quarantine). The animals were housed indi-
vidually and maintained in a room with a temperature
range of 18–26°C (please give temperature in Celsius),
34–68% relative humidity, and 12-h light/dark cycles.
Food and water were supplied ad libitum during quaran-
tine and throughout the study. The animals were fed a
standard rodent maintenance diet. The animal protocol
was approved by Institutional Animal Care & Use Com-
mittee (IACUC), WRAIR, and the research was conducted
in compliance with the Animal Welfare Act and other fed-
eral statutes. Regulations relating to animals and experi-Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
Page 3 of 14
(page number not for citation purposes)
ments involving animals adhered to principles stated in
the Guide for the Care and Use of Laboratory Animals,
NRC Publication, 1996 edition.
Pharmacokinetic (PK) study
Traditional PK studies involve intermittent blood sam-
pling and subsequent determination of drug concentra-
tions in whole blood and plasma. The Culex automated
blood sampler provides a way for blood withdrawal at
preprogrammed intervals, which is more accurate and less
labor intensive. Six rats in the PK group were implanted
with a jugular vein catheter under an isofluorane
anesthaesia. After the surgery, rats were allowed to recover
for 96 hours with free access to food and water. The rats
were dosed single i.v. at 3 mg/ml/kg with [14C] DHA (20
μCi/kg), which was prepared as a 25% cremophore/0.9%
saline solution, through the tail vein. A 50–200 μl blood
sample was withdrawn from the jugular vein catheter into
a cooled vial, containing powdered heparin, at 5, 10, 30
minutes and 1, 1.5, 3, 6, 12, 24, 48, 72, 96, and 192 hours
post-dosing according to a preset schedule. PK evaluation
of [14C] DHA in plasma and whole blood, as well as
unchanged DHA in plasma was conducted in individual
rats.
Tissue distribution of [14C] DHA study
Rats treated with a single [14C] DHA dose of 3 mg/20 μCi/
kg intravenously (5 rats per group) were anesthaetized by
isofluorane and euthanized via cardiac puncture at 1, 6,
24, 48, 72, 96, and 192 hours, post-dosing. Blood, liver,
brain, eyes, adrenals, muscle, lungs, heart, liver, kidneys,
spleen, stomach, small intestine, large intestine, perirenal
fat and bone marrow samples were removed from each
animal by gross dissection. The gastrointestinal tract (GI)
was separated into the stomach (oesophagus and stom-
ach), small intestine, and large intestine. Contents were
procured from each GI segment. After flushing with
saline, these and other tissues were stored. Tissues were
rinsed gently, but thoroughly with water to remove
remaining traces of blood before storage. Dissecting
instruments were also washed between tissue procure-
ments to avoid cross-contamination.
For most of the tissues 20% (w/w) aqueous homogenates
of the tissue were prepared. Aqueous homogenates of the
faecal and GI content samples were also prepared. Metab-
olism cages were washed with a solution of 2% Count-off®
and the volume was measured. Radioactivity in the
plasma samples and in aliquots (approx. 0.02–1.0 ml) of
urine and cage washings was determined. The blood cells
(primarily erythrocytes), perirenal fat (approx. 0.2 g),
bone marrow samples (approx. 0.1 ml), and approxi-
mately 300-μl aliquots of the homogenates of faeces, liver,
kidneys, heart, brain, stomach and carcass were solubi-
lized with SolvableTM tissue solubilizer (Perkin-Elmer
Life and Analytical Sciences, Boston, MA). The homoge-
nates of faeces, stomach content, and intestinal contents
were extracted with 50% methanol for 24 hours. Aliquots
of blood and pooled urine samples from selected intervals
were also analysed for DHA content directly.
Total radioactivity in the collected tissue samples were
quantified in duplicate. Weighed tissue aliquots (~0.2 g)
were digested overnight in 2 ml of Solvable® tissue solubi-
lizer (Perkin-Elmer Life and Analytical Sciences, Boston,
MA) at 50°C. Coloured samples were decolourized by
adding a maximum of 0.2 ml of 30% H2O2 for 30–60
minutes. Scintillation cocktail (Hyonic Fluor; Perkin-
Elmer Boston. Massachusetts, USA) was then added and
radioactivity determined in a Perkin-Elmer Tri-Carb 3100
TR scintillation spectrophotometer (Packard Instrument
Co., Downers Grove, Illinois, USA). Faeces and intestinal
contents were thoroughly homogenized before taking
aliquots. Plasma was also analysed using the HPLC-ECD
system to measure the concentration of unchanged DHA,
as described by Li et al [6].
Mass balance and elimination of [14C] DHA study
Samples of urine and faeces were collected for a period of
192 hours after a single i.v. injection at 1, 8, 24, 48, 72, 96,
120, 144, 168, and 192 hours from individual stainless
steel Nalgene metabolic cages (Nalgene Company,
Rochester, New York, USA) designed for separate collec-
tion of urine and faeces. Metabolic cages were washed
with a solution of 2% Count-off® (Perkin-Elmer Life and
Analytical Sciences, Boston, Massachusetts, USA) and the
volume was measured. Duplicate portions (0.1 ml urine;
1 ml cage rinse) of each sample were radio-assayed after
the addition of scintillation cocktail. The weights of indi-
vidual faecal samples were obtained and the samples were
subsequently homogenized in four volumes of de-ionized
water. Quadruplicate portions (1.0 ml) of each homoge-
nate were decolourized with 30% hydrogen peroxide, and
digested with Solvable® tissue solubilizer. After acidifica-
tion with glacial acetic acid and addition of scintillation
cocktail, samples were assayed for radioactivity. The sam-
ples were kept in at -20°C for two weeks prior to analysis.
Metabolic profile of [14C] DHA study
About 2 ml of plasma and urine, and 1 – 2 g of faeces were
used. Conjugates were hydrolyzed by glucuronidase
(1000 FU/ml, Sigma-Aldrich, St. Louis, MO) at pH 4.6,
38°C for 24 hours. Active enzyme was checked by phen-
ophthaleinglucuronide at the end of incubation. Urine
and faecal samples were incubated for 48 hours and fresh
enzyme was added after 24 hours. Total radioactivity in
free, conjugated, and the remaining aqueous fractions
were measured with liquid scintillation counters. Protein
precipitates were dissolved in SolvableR (200 mg in 1 ml)Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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and counted for radioactivity after addition of scintilla-
tion cocktail.
Protein binding of [14C] DHA study
Human blood samples (five men and five women) were
freshly obtained from subject volunteers at the Depart-
ment of Clinical Trials, WRAIR. Rat samples were freshly
collected from five male and five female rats. Equilibrium
dialysis was performed using Teflon dialysis chambers
and Diachema standard membranes as described by Li
and Hümpel [20]. The GD-4/90 Equilibrium Dialyzer
(MM Developments, Ottawa) contained 20 micro-dialysis
cells (2.0 ml/chamber). The molecular weight cutoff for
dialysis membranes was 5000 D. Equilibrium was
reached after four hours, when cells were rotated at 16
rpm and 37°C. Drugs were dissolved in plasma samples
with various concentrations (0.15 – 57800 ng/ml) and all
experiments were carried out for five hours.
HPLC-ECD method
The analysis of cold DHA in plasma was performed
according to a previously described HPLC method [21]
with the following modifications: for simultaneous deter-
mination of artemisinin and DHA (artemisinin as an
internal standard), the Agilent Eclipse XDB-C18 column 5
μm (4.6 × 150 mm) was used with an isocratic mobile
phase consisting of 40% acetonitrile: 60% ESA Acid
Metabolite A (70–4835) in the reductive mode (-400 mV)
for the quantification of DHA. Validation and reproduci-
bility were evaluated and a lower limit of quantitation
(LLQ) of 2.31 ng/ml for DHA was determined. The inter-
and intra-day coefficient of variation for accuracy and pre-
cision were all within ± 10%.
Data evaluation
For pharmacokinetics, the concentration-time data of
[14C] DHA in plasma and whole blood collected during
the 192 hour treatment period was fitted to a three-com-
partment open model using a nonlinear, extended least-
square fitting procedure (WinNonlin 5.2, Pharsight Cor-
poration, Cary, NC) using weighted (1/concentration)
nonlinear regression. The area under the curve (AUC) was
determined by the linear trapezoidal rule with extrapola-
tion to infinity based on the concentration of the last time
point divided by the terminal rate constant. Extrapola-
tions to time zero were done using zero concentration for
intravenous dosing and using C0 values determined from
the three-compartment model equation at time zero by
i.v. route. Mean clearance rate (CL) was determined by
dividing the dose by the AUCinf for i.v. injection. Mean
residence time (MRT) was determined by dividing the
area under the first moment curve (AUMC) by the AUC.
The volume of distribution at steady state (Vss) was calcu-
lated as the product of CL and MRT. The concentration-
time data of unchanged DHA was fitted to a two-compart-
ment open model. Statistical analysis was conducted with
Microsoft Excel using a Student's t-test for dependent sam-




The results of the analysis of the i.v. formulation of [14C]
DHA are designated at 3 mg/20 μCi/ml in this study.
Chemical concentration and radioactivity analysis of sam-
ples taken from each dosing solution indicated the formu-
lation was homogeneous. The mean concentration of
DHA in the i.v. formulation was 2.87 to 3.12 mg/ml. The
radioactivity content of the i.v. formulation was detected
between 20.54 and 23.62 μCi/ml. The radiochemical
purity of [14C] DHA was determined to be greater than
98% while cold DHA was greater than 99%.
Pharmacokinetics of [14C] DHA and unchanged DHA
Pharmacokinetic parameters calculated from mean levels
of total radioactivity and unchanged DHA in either whole
blood or plasma are shown in Table 1 after single i.v.
administration of [14C] DHA. The concentration-time
data of [14C] DHA in plasma and blood (Figure 1) col-
lected during the 192 hours of the treatment period were
fitted to a three-compartment open model. Radioactivity
derived from [14C] DHA was eliminated from plasma in
three phases with half-lives of 0.21, 15.49, and 75.57
hours, and from blood in three phases with half-lives of
0.18, 19.68, and 122.13 hours. Unchanged DHA was
eliminated from the plasma in two apparent phases with
half-lives of 0.25 and 1.03 hours (Table 1).
Peak concentrations (Cmax) of [14C] DHA and unchanged
DHA in plasma at one minute were 3,446 ng equivalents/
ml and 1,999 ng/ml, respectively. The corresponding
AUCs of [14C] DHA and unchanged DHA were 21,014
and 933 ng equivalents·h/ml, suggesting DHA is exten-
sively metabolized in animals. Similar to the AUC, the
volume of distribution at steady state (Vss) was 8,216 ml/
kg for radiolabeled drug and 1,658 ml/kg for unchanged
DHA. Calculated clearance values (CL) for radioactivity
and unchanged DHA in plasma were 144.63 and 3,350.02
ml/hr/kg, respectively (Table 1).
Following the i.v. administration of [14C] DHA four peaks
of radioactivity were detected (Figure 1) within first 24
hours. The first peak concentration of radioactivity, 3,446
and 3,105 ng equivalents/g, was present in plasma and
whole blood at one minute (earliest measured time point)
after dosing. The second peak formed at 11 minutes with
plasma at 2,373 ng equivalents/ml and at 56 minutes for
whole blood with 1,558 ng equivalents/g. the third peak
was seen at 1.7 hours with 863 ng equivalents/ml in
plasma and at two hours with 978 ng equivalents/ml inMalaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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blood. The fourth peak concentration of radioactivity
appeared at 6 hours with 584 and 833 ng equivalents/ml
in plasma and blood, respectively, revealing an enterohe-
patic circulation of [14C] in rats. Only two concentration
peaks of unchanged DHA were found in plasma. The peak
concentration of unchanged DHA was 1999 ng/ml at one
minute and the second peak was 1638 ng/ml at 23 min-
utes after the intravenous injection.
Tissue distribution of [14C] DHA
In tissues collected at 1 hr, approximately 62.6% of radio-
activity in the total measured tissues was amassed in the
small intestine and its content. Lesser amounts of radioac-
tivity were distributed in other tissues (Table 2). The total
amount of radioactivity in all measured tissues per gram
was 87,187 ng equivalents. Six hours after the injection,
high levels of radioactivity were still present in the intes-
tine, colon, and in their contents with slow loss; however,
drug distribution was significantly increased in other tis-
sues such as kidney, spleen, liver, heart, adrenals, blood,
muscle, colon and colon content (Figure 2). The total
amount of radioactivity in all measured tissues per gram
at six hours was similar to the 1 hr measurement at 86023
ng equivalents/g. The remarkable increases of radioactiv-
ity in other tissues at six hours may relate to redistribution
from tissues, enterohepatic circulation, or the presence of
DHA metabolites which have a smaller volume of distri-
bution than DHA.
From 24 to 192 hours, measured radioactivity rapidly
declined in all tissues except for the spleen (Figure 2). The
total amount of radioactivity in all measured tissues per
gram was 21,457, 16,390, 15,831, 11,385 and 13,961 ng
equivalent at 24, 48, 72, 96, and 192 hours, respectively
(Table 2). At 192 hours after dosing, residual activity
(close to 5.53% of total amount collected) was still
detected in some tissues and the highest levels of radioac-
tivity were measured in spleen, kidney, adrenals, large
intestine content, liver, and lungs. Radioactivity in the
blood and plasma was measured in quantifiable levels at
192 hours after the single i.v. injection (Figure 1). Radio-
activity in whole blood was always higher (1.8–4.6 fold)
than in plasma throughout the period measured.
Unchanged DHA was completely eliminated within 6 hr
after 5–6 half-lives (Table 2), indicating that the long-last-
ing metabolites of DHA (> 192 hr) in the rats may be also
related to slow release of DHA binding from RBC or other
tissues (e.g. spleen) with subsequent metabolism and the
enterohepatic circulation.
During the treatment period, measured levels of radioac-
tivity were more than two-fold higher in the brain than in
plasma; the AUC of radioactivity from 0 to 192 hours was
34,189 ng·h/g in the brain and 20,750 ng·h/ml in the
plasma. Excepting small intestine (35.25%), the highest
levels of the radioactivity were detected in the spleen. The
measured amount was 4,387 ng equivalents/g at 1 hr after
dosing. From 6 to 24 hours, the amount decreased from
3,685 to 3,061 ng equivalents/g (Table 2). However, the
amount of radioactivity increased again to 4,216 ng
equivalents/g by 48 hours; thereafter, the level constantly
increased up to 5,170 ng equivalents/g at 192 hours, with
was the highest AUC (617,495 ng·h/g) and the highest
percentage (14.58%) of total amount of radioactivity in
spleen, when compared to other tissue. In other measured
tissues, the highest to lowest AUCs were found as the fol-
lows: large intestine content (588,542 ng·h/g), adrenals
(448,390 ng·h/g), kidneys (191,781 ng·h/g), liver
Table 1: Comparison of main pharmacokinetic parameters of [14C] dihydroartemisinin (DHA) in plasma and blood, as well as 
unchanged DHA in plasma at 3 mg/kg, in rats following a single intravenous dose
14C-Dihydroartemisinin 3 mg/20 μCi/kg Unchanged DHA 3 mg/kg
Parameters Plasma Three-compartment Blood Three-compartment Plasma Two-compartment
Cmax (ng/ml) 3446 ± 396 3105 ± 430 1999 ± 507
Tmax (hr) 0.02 0.02 0.02
AUCinf. (ng*h/ml) 21014 ± 2718 52690 ± 4971 933.2 ± 125.4
t1/2 – alpha (hr) 0.21 ± 0.05 0.18 ± 0.02 0.25 ± 0.04
t1/2 – beta (hr) 15.49 ± 1.64 19.68 ± 3.88 1.03 ± 0.19
t1/2 – gamma (hr) 75.57 ± 7.34 122.13 ± 8.73 -
CL (ml/hr/kg) 144.63 ± 18.17 43.58 ± 30.70 3350.02 ± 423.37
Vss (ml/kg) 8216 ± 828 10792 ± 3771 1658 ± 540
MRT (hr) 57.00 ± 2.84 148.57 ± 90.24 0.49 ± 0.12
Cmax at first peak (ng/ml) 3446 ± 396 (0.02 h) 3105 ± 430 (0.02 h) 1999 ± 507 (0.02 h)
at second peak (ng/ml) 2373 ± 195 (0.19 h) 1557 ± 955 (0.94 h) 1638 ± 468 (0.38 h)
at third peak (ng/ml) 863 ± 537 (1.70 h) 978 ± 164 (2.00 h) -
at fourth peak (ng/ml) 584 ± 65.5 (6.00 h) 833 ± 99 (6.00) -
DHA = dihydroartemisinin; MRT = Mean residence time; MAT = Mean arrival time; - = no data is available. Mean ± SD (n = 5).Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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(172,474 ng·h/g), small intestine (131,264 ng·h/g),
heart (104,598 ng·h/g), lung (85,916 ng·h/g), and large
intestine (70,217 ng·h/g) (Table 2).
The longest half-life of radioactivity was measured in the
fat at 131.69 hours, followed by the blood (122.13 h),
spleen (114.02 h), liver (95.18 h), adrenals (92.48 h), tes-
tis (96.24 h), lungs (86.19 h), and so on. In contrast, the
radioactivity lasted much less in the contents of stomach,
small intestine, and large intestine with half-lives of
16.75, 28.73, and 37.20 hours, respectively.
Mass balance determination
The total recovery of radioactivity in excreta (urine and
faeces) and cage rinses collected from animals through
192 hours after single i.v. administration is shown in
Table 3. Through 192 hours after injection, approximately
52.09%, 40.39% and 1.88% of the dose was eliminated in
urine, faeces, and cage rinses, respectively. The urinary
excretion was the major route of elimination, accounting
for 44–61% of the administered dose. Faecal excretion
was the secondary route of elimination, accounting for
27–53% of the administered dose. The recovery of [14C]
DHA from urine, faeces and cage washing solution was
94.36% of total dose during the 9 days of collection.
Urinary and faecal elimination
The elimination parameter estimates after intravenous
dosing of [14C] DHA at 3 mg/kg are presented in Table 3.
Results showed the greater than 74.76% of the total dose
was excreted within first 24 hours. The maximum [14C]
radioactivity concentration in urine was observed with
Multiple peaks of mean concentration were shown in whole plasma (dash line with triangular markers) and in blood (solid line  with circular markers) with the radioactivity (ng equivalents per ml), as well as PK profile of unchanged DHA in plasma (solid  line) following a single 3 mg/20 μCi/kg intravenous injection of [14C]-dihydroartemisinin (14C-DHA) in rats (n = 6) Figure 1
Multiple peaks of mean concentration were shown in whole plasma (dash line with triangular markers) and in 
blood (solid line with circular markers) with the radioactivity (ng equivalents per ml), as well as PK profile of 
unchanged DHA in plasma (solid line) following a single 3 mg/20 μCi/kg intravenous injection of [14C]-dihy-
droartemisinin (14C-DHA) in rats (n = 6).Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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243.48 μg or equivalents per rat at 0.37 days. The elimina-
tion of [14C] label from urine occurred in two phases, fast
and slow, with half-lives of 0.32 and 1.36 days (Figure 3,
top). Similar to urine, fast and slow elimination phases
were also exhibited in faeces. A peak concentration of
292.39 μg equivalents per rat was seen in faecal matter at
0.67 days after dosing. The half-lives of [14C] radioactivity
were 0.35 and 1.29 days for fast and slow phases in faeces,
respectively. The elimination of radioactivity in faeces was
not immediately like urine and was delayed with a lag
time of 0.31 days (Figure 3, bottom), while the lag time
for urine was < 0.02 days.
Metabolite profiles of [14C] DHA
Unchanged DHA was rapidly and completely eliminated
from rats within 6 hours following single i.v. administra-
tion. The total radioactivity (metabolites) lasted longer
than 192 hr in plasma, urine and faeces. Conjugation
studies showed drug conjugation of the dose in plasma
and urine (up to 89% and 95%, respectively) is a major
metabolic pathway of [14C] DHA, and that conjugation is
time-dependent in rats (Table 4). Metabolites of DHA
were quantified before and after hydrolysis with beta-glu-
curonidase to give free and conjugated fractions of
plasma, urine and faeces. In the beginning, within five
minutes after dosing, the drug total conjugation fractions
were similar to free fraction with the ratio of conjugation
to free from 1.07 in plasma. The ratio was increased to
1.86 at 10 minutes and then rapidly increased to 4.48 at 1
hour after dosing. After dosing, the ratio moderately ele-
vated up to 15.1 at 192 hours (Table 4).
Table 2: Distribution (ng equivalents/tissue gram), half lives, and area under the curve (AUC) of [14C]-dihydroartemisinin in main 
organs and tissues of male rats following single intravenous dose at 3 mg/20 μCi/kg and animals were euthanized at 1, 6, 24, 48, 72, 96, 
and 192 hr after dosing (n = 5).
Parameters 1 hr 6 hr 24 hr 48 hr 72 hr 96 hr 192 hr Half-lives (hr) Tissue AUC 
(ng·hr/g)
% of total 
AUC
Blood 936.19 795.07 366.76 252.05 194.59 130.92 118.71 122.13 ± 8.73 45463 ± 6810 1.07
Plasma 591.34 540.83 216.03 93.02 64.70 34.58 22.84 75.57 ± 7.34 20750 ± 1031 0.49
Brain 578.68 326.57 160.11 127.38 138.35 119.67 133.52 72.21 ± 6.33 34189 ± 4885 0.81
Eyes 279.20 239.95 64.78 46.86 51.58 98.06 121.94 75.22 ± 9.40 16519 ± 3048 0.39
Adrenals 5614.75 3451.81 2034.62 3002.03 1630.57 1653.43 1543.60 92.48 ± 44.34 448390 ± 
273502
10.59
Fat 1391.80 218.23 80.24 62.09 61.62 43.52 84.86 131.69 ± 
21.94
25253 ± 1490 0.60
Muscle 698.14 499.29 171.74 163.19 174.04 92.20 115.14 64.45 ± 13.54 36371 ± 6994 0.86
Lungs 1161.72 1040.99 398.52 305.34 303.10 236.70 221.64 86.19 ± 18.00 85916 ± 12999 2.03
Heart 1512.27 1107.89 647.58 527.3 568.43 377.26 443.20 74.35 ± 25.84 104598 ± 
24036
2.47





Kidneys 4097.87 4502.00 2535.56 2324.72 3286.27 1802.63 1819.89 77.90 ± 8.41 191781 ± 
66422
4.53
Liver 4594.85 3516.69 1403.29 1104.94 1503.74 842.90 1270.24 95.18 ± 37.90 172474 ± 
85780
4.07
Stomach 1366.22 932.33 464.21 342.30 337.48 229.69 218.27 72.58 ± 12.98 82125 ± 13428 1.94
Stomach 
Content
36.03 6289.79 22.45 98.12 18.69 11.76 343.37 16.75 ± 16.30 22362 ± 98089 0.53
Large intestine 
(LI)
1818.56 8394.43 1420.58 562.96 509.29 220.41 304.72 62.53 ± 43.59 70217 ± 25001 1.66





8155.95 3014.58 821.84 335.42 389.72 235.61 304.12 49.99 ± 34.89 131264 ± 
24631
3.10
SI Content 46426.85 11387.30 2283.61 633.61 575.05 176.57 250.03 28.73 ± 9.05 1492988 ± 
63053
35.25
Testis 624.14 513.53 176.47 155.78 151.29 123.54 141.04 86.24 ± 40.68 48249 ± 6078 100.00
Total 
Amounts
87186.55 86023.26 21457.06 16390.68 15831.77 11385.67 13961.18 69.03 ± 22.13 4234952.00 1.14
% total 
recovery
34.57 34.10 8.51 6.50 6.28 4.51 5.53
DHA = dihydroartemisinin; MRT = Mean residence time; MAT = Mean arrival time; - = no data is available. MeanMalaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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Protein binding of [14C] DHA with rat and human plasma
[14C] DHA revealed a higher binding percentage with
human and rat plasma proteins (76–82%) when incu-
bated with undiluted plasma samples at concentrations of
0.15 to 57800 ng/ml at 37°C for five hours. There was a
concentration dependent decrease in the binding of [14C]
DHA. At higher concentrations (> 25 ng/ml) the binding
percentage declined from 82% to 66%, indicating that the
maximum binding percentage occurred in the concentra-
tion range of 0.15 – 462 ng/ml (Figure 4, top). The bind-
ing capacity of DHA in rat plasma was not significantly
different with drug concentration vary (Figure 4, bottom).
Discussion
Previous studies have established the role of biliary excre-
tion in the elimination of artemisinin metabolites from
rats [18,22,23] and mice [24]. In the present studies, the
tissue distribution and metabolic profiles of DHA by tis-
sue dissection techniques (TDT) method confirmed the
results from the published literature. Findings from this
study provide evidence of the extent of metabolism of
DHA in rats. The outcomes of this study indicate very little
unchanged DHA is eliminated by direct excretion from
kidneys (<1% of dose); rather most (99%) occurs via
metabolism (hydrolysis and oxidation). Data presented
in this study allows a comprehensive characterization of
DHA with pharmacokinetics, tissue distribution and its
metabolic profiles.
Unchanged DHA was eliminated from plasma with a ter-
minal half-life of 1.03 hours after i.v. administration. The
Vss of unchanged DHA was estimated to be 1,658 ml/kg,
which was a half of Vss of unchanged artesunate (3982 m/
.kg) in rats published previously [18], indicating that
DHA has a relatively small volume of distribution and the
compound was distributed to total body water. The calcu-
lated plasma clearance of DHA was 3,350 ml/hr/kg, which
is less to rat normal hepatic blood flow (4,800 ml/hr/kg).
Mean distribution profile of total radioactivity (ng equivalents per gram tissue) of dihydroartemisinin (DHA) in various tissues  (column) at 1, 6, 24, 48, 72, 96, and 192 hr following a single 3 mg/20 μCi/kg intravenous injection of [14C] DHA in rats (n = 5) Figure 2
Mean distribution profile of total radioactivity (ng equivalents per gram tissue) of dihydroartemisinin (DHA) in 
various tissues (column) at 1, 6, 24, 48, 72, 96, and 192 hr following a single 3 mg/20 μCi/kg intravenous injec-
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This is probably related to uptake and binding of DHA in
red blood cells. The results indicate even though the dis-
tribution of unchanged DHA is apparently limited to total
body water, the radioactivity derived from [14C] DHA was
extensively distributed throughout rats and lasted for an
extended period (at least 192 hours). The average ratio of
blood to plasma per ml was 2.18 during the 192 hr
period. High concentrations of [14C] DHA present in RBC
is very important for the anti-malarial agent in blood stage
treatment. The drug concentration in RBC is about 3.54
times higher than that in plasma by calculated using a
haematocrit of 0.48, indicating that the powerful anti-
malarial potency of DHA in animal species and humans
may relate to the high drug levels in the RBC.
An understanding of artemisinin-associated neurotoxicity
in vivo requires knowledge of the penetration of the cere-
brospinal fluid (CSF) by these drugs. Such data is sparse.
Artemisinin derivatives cross the blood-brain barrier in
rats [24]. Artesunate is converted stoichiometrically to
DHA, which is highly lipid soluble and has a low molec-
ular mass (284 Da), favouring penetration of CSF [25].
Since DHA has relatively low solubility in water, it should
be able to cross cell membranes and be conjugated. After
DHA treatments in patients, no unchanged DHA was
detected in CSF but [14C] DHA levels in CSF increased
with time while DHA levels in plasma fell, suggesting con-
tinued influx, with a slower efflux of DHA. [14C] DHA
may accumulate in CSF during frequent DHA dosing [25].
In the present study, the radioactivity in brain tissues
(AUC: 34,189 ng·h/g) was more than twice as high as in
plasma (AUC: 20750 ng·h/ml). The half-life of [14C]
DHA in brain tissue was 72.21 hr, which was also longer
than that in plasma, 63.04 hr. The results indicated that
the residence time of [14C] DHA is longer in the brain than
that in plasma. This may reflect a sink effect of DHA and/
or other metabolites and an uptake transfer by lipid-rich
brain structures [25]. The presence of DHA metabolites in
brain tissue, and any association with neurotoxicity is cur-
rently unknown.
The current study demonstrates DHA undergoes rapid
metabolism via conjugation and biliary elimination. The
results of the tissue distribution studies show 53–86% of
total radioactivity to be found in the content of small
intestine within the first hour after i.v. dosing. At one hour
after dosing most of the [14C] was present in the liver,
where it was excreted into the intestines via bile ductules;
this suggests the higher hepatic biotransformation of
DHA is similar to metabolic profile of artesunate and
other artemisinin compounds [18,22,23]. Urinary and
faecal excretion data obtained after i.v. administration of
[14C] DHA demonstrated that approximately 52% of the
dose was eliminated in urine and 40% in faeces within
192 hours after dosing. The finding also suggests a major-
ity of [14C] DHA may be first excreted in bile and re-
absorbed from intestines.
The multiple radioactivity peaks shown in the plasma,
blood and various tissues indicate the presence of entero-
hepatic circulation of [14C] DHA in all animals. The drug
plasma concentration profile revealed that [14C] DHA
Table 3: Percentages of renal and fecal excretion of total radiolabel following single intravenous administration of [14C] 
dihydroartemisinin with 25% cremophore EL/0.9% saline formulation at 3 mg/kg to rats (n = 5).
Sample time (days) Urine Feces Cage wash
0–0.04 4.18 ± 1.06
0.04–0.33 25.49 ± 1.98 1.52 ± 0.58
0.33–1.0 14.01 ± 5.11 29.56 ± 11.75
1–2 4.78 ± 1.30 6.14 ± 1.71
2–3 1.63 ± 0.92 1.64 ± 0.78
3–4 0.72 ± 0.19 0.78 ± 0.31
4–5 0.57 ± 0.25 0.46 ± 0.09
5–6 0.46 ± 0.37 0.15 ± 0.06
6–7 0.16 ± 0.02 0.11 ± 0.05
7–8 0.09 ± 0.04 0.04 ± 0.04
Total 52.09 ± 8.94 40.39 ± 13.22 1.88 ± 2.27
Ratio of excretion (urine/feces) 1.37 ± 0.39
Balance (% of dose) 94.36 ± 16.71
Elimination parameters
Peak height (μg/rat) 234.48 ± 33.74 292.39 ± 150.29
Peak time (days) 0.37 ± 0.06 0.67 ± 0.09
Fast elimination phase (days) 0.32 ± 0.07 0.35 ± 0.11
Slow elimination phase (days) 1.36 ± 0.25 1.29 ± 0.47
All values expressed as % of dose, mean ± SD, n = 5.Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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Individual elimination profile of total radioactivity (μg equivalents per rat) of dihydroartemisinin (DHA, circular markers) in  urine (top) and faeces (bottom) and computer fitted curves (solid line) by pharmacokinetic parameters following a single 3 mg/ 20 μCi/kg intravenous injection of [14C] DHA in rats during 8 days collection (n = 5) Figure 3
Individual elimination profile of total radioactivity (μg equivalents per rat) of dihydroartemisinin (DHA, circu-
lar markers) in urine (top) and faeces (bottom) and computer fitted curves (solid line) by pharmacokinetic 
parameters following a single 3 mg/20 μCi/kg intravenous injection of [14C] DHA in rats during 8 days collec-
tion (n = 5).Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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formed a second, third and fourth peak at 11 minutes, 1.7
h and 6 h, respectively, after i.v. injection (Figure 1). This
again suggests that the multiple increases in drug concen-
tration are due to either enterohepatic circulation or the
presence of a multiple absorption phases [26-28]. Usu-
ally, the multiple peaks in oral concentration-time pro-
files, following drug administration, are a result of:
discontinuous absorption along the gastrointestinal tract,
post-absorptive storage and release, and/or enterohepatic
circulation [29]. Therefore, the multiple peaks in the
present study and the high amounts of radioactivity in bil-
iary excretions after the i.v. injection of DHA strongly sug-
gest the presence of enterohepatic circulation [30-33].
Conclusion
The binding capacities of [14C] DHA with human and rat
plasma at higher percentages, 76–82%, are seen in a con-
centration dependent manner. Radioactivity DHA
showed very longer half-lives of 75.57 and 122.13 hr in
plasma and blood, respectively when compared to
unchanged DHA with only 1.03 hr, indicating long-last-
ing metabolites presented in this study. The drug clear-
ance and distribution volume were 43.58–144.63 ml/hr/
kg and 8216–10792 ml/kg, respectively, for total radioac-
tivity, but were 3350 ml/hr/kg and 1658 ml/kg, respec-
tively, for unchanged DHA. High tissue distribution was
found in rat spleen, followed by kidneys, adrenals, liver,
Table 4: Distribution, concentration and half-lives of [14C] dihydroartemisinin (DHA) in total, free, glucuronide and other conjugation 
fractions in plasma or urine following a single intravenous dose at 3 mg/20 μCi/kg in rats.
Time Total Free fraction Glucuronide conjugation Other conjugation fraction
Plasma (n = 5)
0 0.00 0.00 0.00 0.00
0.017 3446.38 ± 396.35 2253.63 ± 537.31 403.87 ± 124.77 583.17 ± 155.52
0.083 2279.43 ± 213.77 925.14 ± 226.81 413.56 ± 69.46 589.70 ± 102.30
0.167 2090.86 ± 180.56 697.05 ± 88.04 480.62 ± 49.17 818.11 ± 88.12
0.25 1987.48 ± 378.69 685.05 ± 193.99 360.93 ± 65.83 684.75 ± 161.05
0.50 1489.58 ± 231.59 461.20 ± 56.83 305.81 ± 26.23 627.62 ± 59.19
0.75 654.49 ± 87.56 157.51 ± 28.11 131.60 ± 29.09 341.12 ± 66.12
1.0 514.20 ± 139.37 105.36 ± 55.10 122.76 ± 36.01 348.30 ± 125.91
1.5 419.48 ± 17.06 75.83 ± 9.85 74.17 ± 11.64 268.16 ± 14.76
2 589.26 ± 154.02 90.58 ± 33.58 110.13 ± 44.55 407.78 ± 112.11
3 466.65 ± 82.13 74.40 ± 16.25 80.73 ± 14.20 321.61 ± 69.08
6 584.41 ± 65.49 51.49 ± 15.64 49.34 ± 22.19 363.63 ± 162.04
8 481.59 ± 79.35 49.44 ± 13.34 57.72 ± 13.56 388.11 ± 72.73
24 253.62 ± 78.47 14.46 ± 3.15 20.04 ± 5.05 188.12 ± 47.66
48 79.17 ± 6.71 7.41 ± 3.24 8.55 ± 1.68 77.07 ± 14.36
72 64.38 ± 14.66 4.89 ± 1.83 4.31 ± 1.19 48.23 ± 12.74
96 35.26 ± 6.54 2.09 ± 1.39 2.25 ± 0.87 25.39 ± 7.32
192 13.48 ± 3.65 1.01 ± 0.92 0.76 ± 0.72 14.49 ± 1.62
AUC (ng·h/ml) 21708 ± 2695 2188.2 ± 286.4 2177.6 ± 299.6 14193.6 ± 6838.7
t1/2 (hr) 15.49 ± 1.64 4.01 ± 0.99 6.66 ± 1.04 20.25 ± 1.32
% of total 100.2 ± 12.68 10.08 ± 1.32 10.03 ± 1.38 79.14 ± 8.22
Urine (n = 5)
0 0.00 0.00 0.00 0.00
0.04 37186.4 ± 8200.9 2253.63 ± 113.44 1611.28 ± 756.20 21546.88 ± 8219.11
0.33 228363.9 ± 20101.9 2693.12 ± 1293.63 8359.94 ± 1428.22 39881.66 ± 5139.02
1.0 123776.8 ± 38621.3 535.48 ± 339.64 732.58 ± 373.98 10784.80 ± 6618.73
2.0 42340.5 ± 8839.2 184.08 ± 70.94 97.20 ± 50.00 2003.77 ± 1218.99
3.0 14248.3 ± 6958.5 86.77 ± 56.02 29.60 ± 15.80 655.31 ± 605.27
4.0 6355.5 ± 1351.3 43.20 ± 26.91 17.54 ± 11.47 278.99 ± 208.65
5.0 4984.6 ± 1922.7 35.21 ± 39.14 12.70 ± 9.90 310.60 ± 306.84
6.0 4006.4 ± 2925.2 22.16 ± 28.94 7.77 ± 3.88 289.69 ± 338.11
7.0 1451.9 ± 149.2 9.75 ± 4.98 6.21 ± 2.92 147.26 ± 104.46
8.0 780.1 ± 344.4 5.77 ± 3.86 3.28 ± 1.66 91.76 ± 59.41
AUC (ng·h/ml) 43624 ± 10214 2213.6 ± 933.4 5069.3 ± 928.2 35657.7 ± 9342.1
t1/2 (day) 1.36 ± 0.25 1.25 ± 0.11 1.30 ± 0.16 1.64 ± 0.11
% of total 98.43 ± 23.38 5.11 ± 1.45 12.22 ± 3.14 82.67 ± 3.96
AUC = area under curve; t1/2 = half-lifeMalaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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Individual protein binding of 14C-DHA in male human (top) and male rat (bottom) plasma (triangle markers) and mean value in  the human plasma (solid line) after incubation in variable concentrations of 14C-DHA (0.15, 0.74, 3.7, 18.5, 92.5, 462, 2312,  11560, and 57800 ng/ml) at 37°C for 5 hours (n = 3) Figure 4
Individual protein binding of 14C-DHA in male human (top) and male rat (bottom) plasma (triangle markers) 
and mean value in the human plasma (solid line) after incubation in variable concentrations of 14C-DHA (0.15, 
0.74, 3.7, 18.5, 92.5, 462, 2312, 11560, and 57800 ng/ml) at 37°C for 5 hours (n = 3).Malaria Journal 2009, 8:112 http://www.malariajournal.com/content/8/1/112
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during the 192 hr period. In rat brain, the total concentra-
tion of [14C] was 2-fold higher than that in plasma, indi-
cating the radioactivity could easily penetrate the brain-
blood barrier. Total radioactivity distributed in RBC was
about three- to four-fold higher than that in plasma, sug-
gesting that the powerful anti-malarial potency of DHA in
treatment of blood stage malaria may relate to the high
RBC binding. Biliary excretion and multiple concentra-
tion peaks of DHA has been demonstrated with high
excretion via bile and approximately 89–95% dose of con-
jugations in blood, urine and faeces. However, the major-
ity of elimination of [14C] DHA is through urinary
excretion (52% dose) due to a most likely drug re-absorp-
tion in the intestines and enterohepatic circulation, as
suggested by the biliary metabolism and the multiple con-
centration peaks in blood, plasma and tissues. The long-
lasting metabolites of DHA (> 192 hr) in the rats may be
also related to slow release of DHA binding from RBC or
other tissues (e.g. spleen) with subsequent metabolism
and the enterohepatic circulation.
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